| Date | Title | Description |
| 25.04.2023 | Vedanta Biosciences Raises $106.5M in Funding | Vedanta Biosciences, a Cambridge, MA-based clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, raised $106.5M in funding.
The investor syndicate was co-led by new invest... |
| 25.04.2023 | Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies | Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that it has... |
| 05.10.2021 | Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA | Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that its Phase 2 clinical trial of VE303, an orally administered investigation... |
| 05.10.2021 | Vedanta Announces Positive Topline Phase 2 Data for VE303 in High- Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA | Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that its Phase... |
| 22.07.2021 | Vedanta picks up $68M Series D | Vedanta Biosciences has raised $68 million in a round led by affiliates of Magnetar Capital. Based in the Boston area, the company uses bacteria from the human microbiome to develop immunotherapies that treat immune-related disorders and in... |
| 21.07.2021 | Vedanta Biosciences Raises $68M in Series D Financing | Vedanta Biosciences, Inc., a Cambridge, Mass.-based clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, closed a $68m Series D financing.
The r... |
| 21.07.2021 | Vedanta Biosciences Completes $68M Series D |
CAMBRIDGE, MA, Vedanta Biosciences, a clinical-stage microbiome company, has raised a $68M Series D financing led by affiliates of Magnetar Capital.
>> Click here for more funding data on Vedanta Biosciences
>> To export Ved... |
| 21.07.2021 | Vedanta raises $68M, reveals setback to Bristol Myers alliance
RealTime Monitoring | Vedanta Biosciences has raised $68 million to take a microbiome candidate into phase 3. The biotech also used the series D update to reveal the failure of its Bristol Myers Squibb checkpoint inhibitor alliance to generate data to support fu... |
| 12.01.2021 | PureTech Founded Entity Vedanta Biosciences Announces $25 Million Investment from Pfizer | Michael Vincent, M.D., Ph.D., Chief Scientific Officer, Inflammation & Immunology Research Unit at Pfizer, to join Vedanta’s Scientific Advisory Board
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to discoverin... |
| 30.12.2020 | Promoters of Vedanta raises $1.4 billion to retire debt, says report | Promoters of Vedanta Ltd have pledged their holding in the company to raise $1.4 billion, mostly for repaying the debt that was coming up for maturity.
In a stock exchange filing, Vedanta said its promoters raised $1 billion debt by issuing... |
| 29.12.2020 | Vedanta raises $400 m from Oaktree | Move to meet its liquidity needs
Vedanta Resources, the holding company of Vedanta, will issue $400 million in notes to an entity of US-based hedge fund Oaktree Capital Group to meet its immediate liquidity requirements.
The notes issued wi... |
| 20.08.2020 | Vedanta raises $1.4 bn via bonds to fund delisting of Indian flagship firm | - |
| 05.12.2019 | Biotech startup Vedanta Biosciences receives $5.8M grant to accelerate development of therapies for multi-drug resistant infections | Vedanta Biosciences, a biotech startup developing a class of drugs that work by modulating the human microbiome, today announced it has been awarded a second research grant from CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceuti... |
| 23.09.2019 | Vedanta Biosciences Raises $16.6 Million Series C-2 Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced... |
| 23.09.2019 | Vedanta Biosciences Inks $16.6M Series C-2 |
CAMBRIDGE, MA, Vedanta Biosciences announced a $16.6M Series C-2 financing round, bringing the total capital raised in its Series C and C-2 round to $62.1M.
>> Click here for more funding data on Vedanta Biosciences
>> To ex... |
| 23.09.2019 | Vedanta Biosciences Raises $16.6M in Series C-2 Financing | Vedanta Biosciences, a Cambridge, MA-based clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, raised $16.6m in Series C-2 fi... |
| 13.05.2019 | Vedanta Biosciences Closes Extended $45.5 Million Series C Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, has raised an a... |
| 26.04.2019 | Vedanta gets green nod for Rs 12,000 crore project | -->
w The project involves oil augmentation to produce up to 4,00,000 BOPD and 250 MMSCFD of associated gas from the oil field and natural gas augmentation to produce up to 500 mmscfd |
| 12.04.2019 | Vedanta raises $1 billion via bond issue | Vedanta Resources, through its wholly owned subsidiary Vedanta Resources Finance II plc, has raised $1 billion (about ₹6,900 crore) through bonds sold in two tranches, resulting in a blended average cost of 8.75 per cent. The average maturi... |
| 01.01.2019 | Vedanta Biosciences Raises $27 Million Series C | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced... |
| 28.12.2018 | Vedanta Biosciences raises $27M in Series C round | The company said it plans to use the funding to support development of its various product candidates, including the Phase I/II VE416 in food allergy and VE800, which is in a Phase Ib/II study combined with Bristol-Myers Squibb’s Opdivo (ni... |
| 26.12.2018 | Vedanta Biosciences Raises $27M in Series C Financing | Vedanta Biosciences, a Cambridge, Mass.-based clinical-stage company developing therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, raised $27m in Series C financing.
Backers in... |
| 29.08.2018 | Vedanta receives Rs 9.74-billion penalty for illegal mining royalty | In a move to recover the gains made from alleged illegal mining, the Goa's directorate of mines and geology has issued a Rs 9.74 billion demand notice to Vedanta towards non-payment of royalty for the financial years 2011 to 2013.
The compa... |
| 19.06.2018 | 15 Boston Microbiome Startups to Watch | “Bacteria, it’s the only culture some people have!”
If you spot someone wearing a tee shirt with that saying, there is some chance they work at a microbiome startup. If they don’t, it’s probably worth looking into.
The human microbiome is a... |
| 12.03.2018 | Vedanta raises $1.7 b via bonds issue | Vedanta Resources has raised $1.7 billion (Rs 9,500 crore) through issue of bonds, the largest-ever offering by any Indian corporate, which will be used to part-finance Cairn India acquisition.
“Vedanta Resources Plc announced the pricing o... |
| 08.08.2017 | Reality vs. hype: A macro look at the microbiome market | Silicon Valley Bank has gone a long way to answering that question with its recent report, titled: “Emerging Healthcare: Microbiome Investment Trends.”
The report captured some important financial trends, noting that 2014 was a pivotal comi... |
| 06.06.2016 | Vedanta Biosciences Raises $50 Million Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, pioneering the development of a new class of therapies designed to modulate the human microbiome, today announced that it has raised $50 million in new equity investments. New investor... |
| 06.06.2016 | Vedanta Biosciences Closes $50 Million Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, pioneering the development of a new class of therapies designed to modulate the human microbiome, today announced that it has raised $50 million in new equity investments. New investor... |
| 06.06.2016 | Invesco Asset Management Leads $50M Financing For Vedanta Biosciences | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, pioneering the development of a new class of therapies designed to modulate the human microbiome, today announced that it has raised $50 million in new equity investments. New investor... |
| 06.06.2016 | Microbiome Therapeutics Company Vedanta Biosciences Raises $50M in VC Funding | Vedanta Biosciences, a Cambridge, MA-based developer of a new class of therapies designed to modulate the human microbiome, raised $50m in new equity funding.
Backers included new investors Rock Springs Capital, Invesco Asset Management and... |
| 06.06.2016 | Rock Springs Capital Leads $50M Financing For Vedanta Biosciences | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, pioneering the development of a new class of therapies designed to modulate the human microbiome, today announced that it has raised $50 million in new equity investments. New investor... |
| 05.05.2015 | Vedanta takes $3B write-down on Cairn | Vedanta Ltd today reported a consolidated net loss of Rs 19,228.12 crore in the quarter ended March 31 due to impairment charge relating largely to Cairn IndiaBSE -0.71 % acquisition goodwill.
ADVERTISEMENT
The company in the period under r... |
| 26.12.2013 | 5 biotech startups braving the new world of microbiome therapies | Drug discovery firm Second Genome, founded in 2010, raised an $11.5 million Series A round this year and secured a deal with Janssen to advance new microbiome-based therapies for ulcerative colitis. In its own pipeline, the company says it’... |
| 23.05.2013 | Vedanta raises $1.7bn via bonds to repay part of Cairn debt | Vedanta Resources will use the $1.7 billion (Rs 9,500 crore) it has raised through bonds to partly repay the debt taken for its Cairn India acquisition.
"Vedanta Resources Plc announced the pricing of the offering of bonds in the aggre... |
| 27.05.2011 | Vedanta raises $1.7 billion | Vedanta Resources said on Friday it has raised $1.7 billion (Rs 7,425 crore) through private placement of bonds to part-finance its $9.6-billion acquisition of Cairn India.
"This represents the largest non-banking corporate bond issuan... |
| 27.05.2011 | Vedanta raises USD 1.65 billion to part-finance Cairn deal | Vedanta Resources on Friday said it has raised USD 1.65 billion (Rs 7,425 crore) through private placement of bonds to part-finance its USD 9.4 billion acquisition of Cairn India.
"This is a landmark transaction and represents largest ... |
| - | 5 biotech startups braving the new world of microbiome therapies | In the same way that great advances in our understanding of the human genome sparked new opportunities for biotech companies in the early 2000s, growing knowledge about how microbes in the human body affect health has paved the way for a sm... |
| - | Vedanta Biosciences raises $27M in Series C round | The Bill & Melinda Gates Foundation is one of several organizations funding the latest round of financing for a company that is developing microbiome-based drugs in several indications.
Cambridge, Massachusetts-based Vedanta Biosciences... |
| - | Vedanta Biosciences | “Vedanta Biosciences, Inc.” |
| - | Reality vs. hype: A macro look at the microbiome market | What hasn’t the microbiome been linked to in mice?
For years, the potential therapeutic value of our so-called “second genome” has been celebrated in successive press releases from researchers around the world. But there’s always a gulf bet... |
